Biomechanical Parameters of Gait in Patients With Parkinson's Disease and Parkinsonian Syndromes

This study has been terminated.
Sponsor:
Collaborator:
French National Institut of Health and Medical Research
Information provided by (Responsible Party):
Marie-laure Welter, Groupe Hospitalier Pitie-Salpetriere
ClinicalTrials.gov Identifier:
NCT00139321
First received: August 30, 2005
Last updated: January 7, 2013
Last verified: January 2013
  Purpose

Gait disorders and falls are frequent in patients with parkinsonian syndromes. In patients with Parkinson's disease (PD), these signs occurred later during the course of the disease in comparison to patients with other degenerative parkinsonian disorders. The pathophysiology of these symptoms are still not fully understood. Gait initiation challenges the balance control system as the body moves from an upright stable static posture to a continuously unstable gait. The aim of this study is to analyse the gait initiation process in patients with parkinsonian disorders.


Condition Intervention
Gait Disorders, Neurologic
Device: Force platform and electromyography

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Biomechanical Parameters of Gait in Patients With Parkinson's Disease and Parkinsonian Syndromes

Resource links provided by NLM:


Further study details as provided by Groupe Hospitalier Pitie-Salpetriere:

Primary Outcome Measures:
  • Biomechanical gait initiation parameters

Estimated Enrollment: 110
Study Start Date: June 2004
Study Completion Date: July 2007
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients able to walk without assistance
  • Patients with Parkinson's disease or other degenerative parkinsonian syndromes (progressive supranuclear palsy [PSP], multiple system atrophy [MSA], corticobasal degeneration [CBD], etc.)

Exclusion Criteria:

  • Other parkinsonian syndromes
  • Dementia
  • Neuroleptic treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00139321

Locations
France
Centre d'Investigation Clinique-Hôpital Pitié-Salpetriere
Paris, France, 75013
Sponsors and Collaborators
Groupe Hospitalier Pitie-Salpetriere
French National Institut of Health and Medical Research
Investigators
Study Director: Yves Agid, MD, PhD CIC-Pitié-Salpêtrière
  More Information

No publications provided

Responsible Party: Marie-laure Welter, MD, PhD, Groupe Hospitalier Pitie-Salpetriere
ClinicalTrials.gov Identifier: NCT00139321     History of Changes
Other Study ID Numbers: RBM0260
Study First Received: August 30, 2005
Last Updated: January 7, 2013
Health Authority: France: Ministry of Health

Keywords provided by Groupe Hospitalier Pitie-Salpetriere:
Gait disorders
Postural instability
parkinsonian syndrome
Gait initiation
Parkinson's disease
Adults

Additional relevant MeSH terms:
Nervous System Diseases
Parkinson Disease
Parkinsonian Disorders
Gait Disorders, Neurologic
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Neurologic Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on July 20, 2014